Skip to main content

Table 2 Overview of published MAIC in SpA*

From: The need for comparative data in spondyloarthritis

Year

Patient-level data

Published data

Sponsor

Type of publication

Treatment A (trial name; ClinicalTrials.gov identifier)

Treatment B (trial name; ClinicalTrials.gov identifier)

Ankylosing spondylitis

 2016

Secukinumab (MEASURE 2; NCT01649375)

Adalimumab (ATLAS; NCT00195819)

Novartis

Abstract [5]

 2016

Adalimumab (ATLAS; NCT00195819)

Secukinumab (pooled MEASURE 1 [NCT01358175], MEASURE 2 [NCT01649375])

Abbvie

Abstract [6]

 2016

Secukinumab (MEASURE 2; NCT01649375)

Adalimumab (ATLAS; NCT00195819)

Novartis

Abstract [7]

 2016

Secukinumab (MEASURE 1; NCT01358175)

Adalimumab (ATLAS; NCT00195819)

Novartis

Abstract [8]

 2016

Secukinumab (pooled MEASURE 1 [NCT01358175], MEASURE 2 [NCT01649375])

Adalimumab (ATLAS; NCT00195819)

Novartis

Abstract [9]

 2017

Secukinumab (pooled FUTURE 1 [NCT01392326], FUTURE 2 [NCT01752634])

Golimumab (GO-RAISE; NCT00265083)

Novartis

Abstract [10]

 2017

Secukinumab (pooled FUTURE 1 [NCT01392326], FUTURE 2 [NCT01752634])

Golimumab (GO-RAISE; NCT00265083)

Novartis

Abstract [11]

 2017a

Secukinumab (MEASURE 2; NCT01649375)

Adalimumab (ATLAS; NCT00195819)

Novartis

Abstract [12]

Psoriatic arthritis

 2013

Adalimumab (ADEPT; NCT00195689)

Etanercept (Mease et al. 2004), infliximab (IMPACT 2; NCT00051623)

Abbvie

Manuscript [13]

 2015

Adalimumab (ADEPT; NCT00195689)

Secukinumab (pooled FUTURE 1 [NCT01392326], FUTURE 2 [NCT01752634])

Abbvie

Abstract [14]

 2016

Secukinumab (FUTURE 2; NCT01752634)

Adalimumab (ADEPT; NCT00195689)

Novartis

Abstract [15]

 2016

Secukinumab (FUTURE 2; NCT01752634)

Adalimumab (ADEPT; NCT00195689)

Novartis

Abstract [16]

 2016

Secukinumab (FUTURE 2; NCT01752634)

Etanercept (Mease et al. 2004)

Novartis

Abstract [17]

 2016

Secukinumab (pooled FUTURE 1 [NCT01392326], FUTURE 2 [NCT01752634])

Adalimumab (ADEPT; NCT00195689)

Novartis

Abstract [18]

 2016

Secukinumab (FUTURE 2; NCT01752634)

Infliximab (IMPACT 2; NCT00051623)

Novartis

Abstract [19]

 2016a

Secukinumab (FUTURE 2; NCT01752634)

Adalimumab (ADEPT; NCT00195689)

Novartis

Abstract [20]

 2017

Secukinumab (pooled FUTURE 1 [NCT01392326], FUTURE 2 [NCT01752634])

Interferon (IMPACT 2; NCT00051623)

Novartis

Abstract [21]

 2017a

Secukinumab (FUTURE 2; NCT01752634)

Infliximab (IMPACT 2; NCT00051623)

Novartis

Abstract [22]

 2017a

Secukinumab (FUTURE 2; NCT01752634)

Etanercept (Mease et al. 2004)

Novartis

Abstract [23]

 2017a

Secukinumab (FUTURE 2; NCT01752634)

Adalimumab (ADEPT; NCT00195689)

Novartis

Abstract [24]

 2017

Adalimumab (ADEPT; NCT00195689)

Secukinumab (pooled FUTURE 1 [NCT01392326], FUTURE 2 [NCT01752634])

Abbvie

Manuscript [25]

  1. *Up to December 2017
  2. aCost per responder analysis